Radiation Therapy for Prostate Cancer
in the News:
The safety of patients is of the utmost importance to Fox Chase's Department of Radiation Oncology.
Read more »
Fox Chase - Home to the Nation's Most Experienced
Fox Chase physicians pioneered the state-of-the-art treatments available today, including IMRT and brachytherapy.
- Intensity Modulated Radiation Therapy (IMRT) is the most advanced external beam radiotherapy available.
- Brachytherapy is the use of low-dose rate permanent seed implants and high-dose rate temporary implants.
Newer radiation treatments are effective at killing cancer cells, while minimizing the occurrence of urinary, bowel and sexual problems.
Radiation therapy is often selected as primary treatment for both localized (cancer confined to the prostate) and locally advanced prostate cancer (cancer has spread within the region but has not reached the lymph nodes), depending on several key factors, including your stage of prostate cancer.
Radiotherapy Provides Equal Results to Surgery
For patients with early-stage disease, radiotherapy provides equal outcomes to surgery. Radiation oncologists deliver radiotherapy by external beam (like an X-ray) called IMRT or brachytherapy (implanted radioactive seeds) to treat prostate cancer.
Prostate cancer chemotherapy and/or hormone therapy following treatment with radiation may be recommended for larger or more aggressive tumors because of the high risk that the cancer has spread outside the prostate.
The Newest Treatment Planning Tools
Protons versus Photons for the Treatment of Prostate Cancerby Marc Smaldone, MD
June 14, 2013
Two recent studies have shown that not only are cancer outcomes comparable between patients treated with protons and photons, but that IMRT may result in less gastrointestinal toxicity.
Read more at
Cancer Conversations »
Confronting Cancer Today
See Dr. Eric Horwitz discuss cancer treatment on the
Today Show, June 12, 2009
Dr. Eric Horwitz talks about radiation therapy on ABC News.
ABC News features radiation treatment at Fox Chase.